Yuleima Diaz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yuleima Diaz has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Aitor Barrio
TECNALIA, Basque Research and Technology Alliance (BRTA), Area Anardi 5, 20730 Azpeitia, Spain
1 shared publication - Ana Ibáñez
Universidad de León
1 shared publication - Ana Isabel Paniagua-García
Centre of Biofuels and Bioproducts, Agricultural Technological Institute of Castilla y León, Villarejo de Órbigo, 24358 León, Spain
1 shared publication - Antonio García-Moyano
NORCE Research, Bergen, Norway
1 shared publication - Ephrem Debebe Zegeye
Department of Paraclinical Sciences, Faculty of Veterinary Medicine , Norwegian University of Life Sciences (NMBU) , Ås, Norway
1 shared publication - Idoia Etxeberria
TECNALIA, Basque Research and Technology Alliance (BRTA), Area Anardi 5, 20730 Azpeitia, Spain
1 shared publication
Latest Publications
- Open Access
Antimicrobial Activity of Lignin-Based Alkyd Coatings Containing Soft Hop Resins and Thymol
The growing concern over the transmission of pathogens, particularly in high-risk environments such as healthcare facilities and public spaces, necessitates the development of effective and sustainable antimicrobial solutions. Traditional coatings often rely on metals, which despite their efficacy, pose significant environmental and economic challenges. This study explores the potential of bio-based alkyd resins, supplemented with natural antimicrobial bioadditives, as an eco-friendly alternative to traditional antibacterial and antiviral coatings. Specifically, alkyd formulations incorporating thymol and soft resins extracted from hops were evaluated for antimicrobial and antiviral efficacy, following ISO standards (ISO 22196:2007 and ISO 21702:2019, respectively). The coating formulations showed significant activity against Gram-negative (Escherichia coli) and Gram-positive (Staphylococcus aureus), and Influenza A (H3N2) virus, proving their potential for mitigating pathogen spread. These bio-based coatings not only reduce reliance on harmful chemicals but also align with circular economy principles by repurposing industrial by-products. This innovative approach represents a significant step toward greener antimicrobial technologies, with broad applications in healthcare, public infrastructure, and beyond, especially considering the rising zoonotic disease outbreaks.
Open AccessAntimicrobial Activity of Lignin-Based Alkyd Coatings Containing Soft Hop Resins and Thymol
The growing concern over the transmission of pathogens, particularly in high-risk environments such as healthcare facilities and public spaces, necessitates the development of effective and sustainable antimicrobial solutions. Traditional coatings often rely on metals, which despite their efficacy, pose significant environmental and economic challenges. This study explores the potential of bio-based alkyd resins, supplemented with natural antimicrobial bioadditives, as an eco-friendly alternative to traditional antibacterial and antiviral coatings. Specifically, alkyd formulations incorporating thymol and soft resins extracted from hops were evaluated for antimicrobial and antiviral efficacy, following ISO standards (ISO 22196:2007 and ISO 21702:2019, respectively). The coating formulations showed significant activity against Gram-negative (Escherichia coli) and Gram-positive (Staphylococcus aureus), and Influenza A (H3N2) virus, proving their potential for mitigating pathogen spread. These bio-based coatings not only reduce reliance on harmful chemicals but also align with circular economy principles by repurposing industrial by-products. This innovative approach represents a significant step toward greener antimicrobial technologies, with broad applications in healthcare, public infrastructure, and beyond, especially considering the rising zoonotic disease outbreaks.
- Open Access
Vaccine Candidate Double Mutant Variants of Enterotoxigenic Escherichia coli Heat-Stable Toxin
Heat-stable enterotoxin (ST) producing enterotoxigenic Escherichia coli (ETEC) strains are among the top four enteropathogens associated with moderate-to-severe diarrhea in children under five years in low-to-middle income countries, thus making ST a target for an ETEC vaccine. However, ST must be mutated to abolish its enterotoxicity and to prevent a potential immunological cross-reaction due to its structural resemblance to the human peptides uroguanylin and guanylin. To reduce the risk of eliciting cross-reacting antibodies with our lead STh-A14T toxoid, L9 was chosen as an additional mutational target. A double mutant vaccine candidate immunogen, STh-L9A/A14T, was constructed by conjugation to the synthetic virus-like mi3 nanoparticle using the SpyTag/SpyCatcher technology. This immunogen elicited STh neutralizing antibodies in mice, but with less consistency than STh-A14T peptide control immunogens. Moreover, individual sera from mice immunized with both single and double mutant variants displayed varying levels of unwanted cross-reacting antibodies. The lowest levels of cross-reacting antibodies were observed with STh-L9K/A14T control immunogens, suggesting that it is indeed possible to reduce the risk of eliciting cross-reacting antibodies by mutation. However, mutant-specific antibodies were observed for most double mutant immunogens, demonstrating the delicate balancing act between disrupting cross-reacting epitopes, keeping protective ones, and avoiding the formation of neoepitopes.
Open AccessVaccine Candidate Double Mutant Variants of Enterotoxigenic Escherichia coli Heat-Stable Toxin
Heat-stable enterotoxin (ST) producing enterotoxigenic Escherichia coli (ETEC) strains are among the top four enteropathogens associated with moderate-to-severe diarrhea in children under five years in low-to-middle income countries, thus making ST a target for an ETEC vaccine. However, ST must be mutated to abolish its enterotoxicity and to prevent a potential immunological cross-reaction due to its structural resemblance to the human peptides uroguanylin and guanylin. To reduce the risk of eliciting cross-reacting antibodies with our lead STh-A14T toxoid, L9 was chosen as an additional mutational target. A double mutant vaccine candidate immunogen, STh-L9A/A14T, was constructed by conjugation to the synthetic virus-like mi3 nanoparticle using the SpyTag/SpyCatcher technology. This immunogen elicited STh neutralizing antibodies in mice, but with less consistency than STh-A14T peptide control immunogens. Moreover, individual sera from mice immunized with both single and double mutant variants displayed varying levels of unwanted cross-reacting antibodies. The lowest levels of cross-reacting antibodies were observed with STh-L9K/A14T control immunogens, suggesting that it is indeed possible to reduce the risk of eliciting cross-reacting antibodies by mutation. However, mutant-specific antibodies were observed for most double mutant immunogens, demonstrating the delicate balancing act between disrupting cross-reacting epitopes, keeping protective ones, and avoiding the formation of neoepitopes.